Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease
Abstract
:1. Introduction
2. Structures of SARS-CoV-2 3CLPro
3. Strategies Applied in Developing Protease Inhibitor
3.1. Drug Repurposing
3.1.1. Virtual Screening
3.1.2. Artificial Intelligence (AI) Technology
3.1.3. Other Approaches
3.2. Computer-Aided Inhibitor Design
3.3. Peptidic Inhibitors/Peptidomimetics
3.4. High-Throughput Screening
3.5. Fragment-Based Drug Design
3.6. Other Inhibitors
4. Perspectives
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Hui, D.S.; Azhar, E.I.; Madani, T.A.; Ntoumi, F.; Kock, R.; Dar, O.; Ippolito, G.; McHugh, T.D.; Memish, Z.A.; Drosten, C.; et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 2020, 91, 264–266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaul, D. An overview of coronaviruses including the SARS-2 coronavirus—Molecular biology, epidemiology and clinical implications. Curr. Med. Res. Pract. 2020. [Google Scholar] [CrossRef]
- Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [Google Scholar] [CrossRef] [PubMed]
- Zhai, P.; Ding, Y.; Wu, X.; Long, J.; Zhong, Y.; Li, Y. The epidemiology, diagnosis and treatment of COVID-19. Int. J. Antimicrob. Agents 2020, 55, 105955. [Google Scholar] [CrossRef] [PubMed]
- Kissler, S.M.; Tedijanto, C.; Goldstein, E.; Grad, Y.H.; Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020, 368, 860–868. [Google Scholar] [CrossRef]
- Pillaiyar, T.; Meenakshisundaram, S.; Manickam, M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov. Today 2020, 25, 668–688. [Google Scholar] [CrossRef]
- Lu, H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends 2020, 14, 69–71. [Google Scholar] [CrossRef] [Green Version]
- Tian, X.; Li, C.; Huang, A.; Xia, S.; Lu, S.; Shi, Z.; Lu, L.; Jiang, S.; Yang, Z.; Wu, Y.; et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 2020, 9, 382–385. [Google Scholar] [CrossRef] [Green Version]
- Liu, C.; Zhou, Q.; Li, Y.; Garner, L.V.; Watkins, S.P.; Carter, L.J.; Smoot, J.; Gregg, A.C.; Daniels, A.D.; Jervey, S.; et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent. Sci. 2020, 6, 315–331. [Google Scholar] [CrossRef]
- Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020, 395, 1569–1578. [Google Scholar] [CrossRef]
- Zhang, L.; Jackson, C.B.; Mou, H.; Ojha, A.; Rangarajan, E.S.; Izard, T.; Farzan, M.; Choe, H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. BioRxiv 2020. [Google Scholar] [CrossRef]
- Lu, J.; Cui, J.; Qian, Z.; Wang, Y.; Zhang, H.; Duan, Y.; Wu, X.; Yao, X.; Song, Y.; Li, X.; et al. On the origin and continuing evolution of SARS-CoV-2. Natl. Sci. Rev. 2020, 7, 1012–1023. [Google Scholar]
- Lipsitch, M.; Cohen, T.; Cooper, B.; Robins, J.M.; Ma, S.; James, L.; Gopalakrishna, G.; Chew, S.K.; Tan, C.C.; Samore, M.H.; et al. Transmission dynamics and control of severe acute respiratory syndrome. Science 2003, 300, 1966–1970. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sharif-Yakan, A.; Kanj, S.S. Emergence of MERS-CoV in the Middle East: Origins, transmission, treatment, and perspectives. PLoS Pathog. 2014, 10, e1004457. [Google Scholar] [CrossRef] [Green Version]
- Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273. [Google Scholar] [CrossRef] [Green Version]
- Gordon, D.E.; Jang, G.M.; Bouhaddou, M.; Xu, J.; Obernier, K.; O’Meara, M.J.; Guo, J.Z.; Swaney, D.L.; Tummino, T.A.; Huttenhain, R.; et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. BioRxiv 2020. [Google Scholar] [CrossRef] [Green Version]
- Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020, 181, 281–292. [Google Scholar] [CrossRef]
- Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020, 367, 1444–1448. [Google Scholar] [CrossRef] [Green Version]
- Tai, W.; He, L.; Zhang, X.; Pu, J.; Voronin, D.; Jiang, S.; Zhou, Y.; Du, L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell. Mol. Immunol. 2020, 17, 613–620. [Google Scholar] [CrossRef] [Green Version]
- Kai, H.; Kai, M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens. Res. 2020, 43, 648–654. [Google Scholar] [CrossRef]
- Nieto-Torres, J.L.; DeDiego, M.L.; Verdia-Baguena, C.; Jimenez-Guardeno, J.M.; Regla-Nava, J.A.; Fernandez-Delgado, R.; Castano-Rodriguez, C.; Alcaraz, A.; Torres, J.; Aguilella, V.M.; et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014, 10, e1004077. [Google Scholar] [CrossRef] [PubMed]
- Krishna, G.; Pillai, V.S.; Veettil, M.V. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. Eur. J. Pharmacol. 2020, 885, 173450. [Google Scholar] [CrossRef] [PubMed]
- Omolo, C.A.; Soni, N.; Fasiku, V.O.; Mackraj, I.; Govender, T. Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. Eur. J. Pharmacol. 2020, 883, 173348. [Google Scholar] [CrossRef] [PubMed]
- Su, H.; Su, H.; Zhou, F.; Huang, Z.; Ma, X.; Natarajan, K.; Zhang, M.; Huang, Y. Molecular Insights into Small Molecule Drug Discovery for SARS-CoV-2. Angew. Chem. Int. Ed. 2020. [Google Scholar] [CrossRef]
- Yang, Y.; Xiao, Z.; Ye, K.; He, X.; Sun, B.; Qin, Z.; Yu, J.; Yao, J.; Wu, Q.; Bao, Z.; et al. SARS-CoV-2: Characteristics and current advances in research. Virol. J. 2020, 17, 1–17. [Google Scholar] [CrossRef] [PubMed]
- Kandimalla, R.; John, A.; Abburi, C.; Vallamkondu, J.; Reddy, P.H. Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics. Mol. Neurobiol. 2020. [Google Scholar] [CrossRef]
- Barrantes, F.J. While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs? Front. Physiol. 2020, 11, 820. [Google Scholar] [CrossRef]
- Tiwari, V.; Beer, J.C.; Sankaranarayanan, N.V.; Swanson-Mungerson, M.; Desai, U.R. Discovering small-molecule therapeutics against SARS-CoV-2. Drug Discov. Today 2020. [Google Scholar] [CrossRef]
- Ullrich, S.; Nitsche, C. The SARS-CoV-2 main protease as drug target. Bioorg. Med. Chem. Lett. 2020, 30, 127377. [Google Scholar] [CrossRef]
- Li, G.; De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 2020, 19, 149–150. [Google Scholar] [CrossRef] [Green Version]
- Dai, W.; Zhang, B.; Jiang, X.M.; Su, H.; Li, J.; Zhao, Y.; Xie, X.; Jin, Z.; Peng, J.; Liu, F.; et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020, 368, 1331–1335. [Google Scholar] [CrossRef] [Green Version]
- Mielech, A.M.; Kilianski, A.; Baez-Santos, Y.M.; Mesecar, A.D.; Baker, S.C. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology 2014, 450–451, 64–70. [Google Scholar] [CrossRef]
- Mielech, A.M.; Chen, Y.; Mesecar, A.D.; Baker, S.C. Nidovirus papain-like proteases: Multifunctional enzymes with protease, deubiquitinating and deISGylating activities. Virus Res. 2014, 194, 184–190. [Google Scholar] [CrossRef]
- Barretto, N.; Jukneliene, D.; Ratia, K.; Chen, Z.; Mesecar, A.D.; Baker, S.C. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J. Virol. 2005, 79, 15189–15198. [Google Scholar] [CrossRef] [Green Version]
- Rut, W.; Lv, Z.; Zmudzinski, M.; Patchett, S.; Nayak, D.; Snipas, S.J.; El Oualid, F.; Huang, T.T.; Bekes, M.; Drag, M.; et al. Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design. BioRxiv 2020. [Google Scholar] [CrossRef]
- Zhang, L.; Lin, D.; Sun, X.; Curth, U.; Drosten, C.; Sauerhering, L.; Becker, S.; Rox, K.; Hilgenfeld, R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 2020, 368, 409–412. [Google Scholar]
- Chen, Y.W.; Yiu, C.B.; Wong, K.Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res 2020, 9, 129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, T.W.; Cherney, M.M.; Huitema, C.; Liu, J.; James, K.E.; Powers, J.C.; Eltis, L.D.; James, M.N. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. J. Mol. Biol. 2005, 353, 1137–1151. [Google Scholar] [CrossRef] [PubMed]
- Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J.R.; Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science 2003, 300, 1763–1767. [Google Scholar] [CrossRef] [Green Version]
- Yang, H.; Yang, M.; Ding, Y.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.; Mo, L.; Ye, S.; Pang, H.; et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. USA 2003, 100, 13190–13195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shi, J.; Wei, Z.; Song, J. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: Defining the extra domain as a new target for design of highly specific protease inhibitors. J. Biol. Chem. 2004, 279, 24765–24773. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Z.; Li, Y.; Loh, Y.R.; Phoo, W.W.; Hung, A.W.; Kang, C.; Luo, D. Crystal structure of unlinked NS2B-NS3 protease from Zika virus. Science 2016, 354, 1597–1600. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Zhong, N.; Xue, F.; Kang, X.; Ren, X.; Chen, J.; Jin, C.; Lou, Z.; Xia, B. Three-dimensional domain swapping as a mechanism to lock the active conformation in a super-active octamer of SARS-CoV main protease. Protein Cell 2010, 1, 371–383. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fan, K.; Wei, P.; Feng, Q.; Chen, S.; Huang, C.; Ma, L.; Lai, B.; Pei, J.; Liu, Y.; Chen, J.; et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J. Biol. Chem. 2004, 279, 1637–1642. [Google Scholar] [CrossRef] [Green Version]
- Anand, K.; Palm, G.J.; Mesters, J.R.; Siddell, S.G.; Ziebuhr, J.; Hilgenfeld, R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 2002, 21, 3213–3224. [Google Scholar] [CrossRef]
- Hu, T.; Zhang, Y.; Li, L.; Wang, K.; Chen, S.; Chen, J.; Ding, J.; Jiang, H.; Shen, X. Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure. Virology 2009, 388, 324–334. [Google Scholar] [CrossRef] [Green Version]
- Chen, S.; Hu, T.; Zhang, J.; Chen, J.; Chen, K.; Ding, J.; Jiang, H.; Shen, X. Mutation of Gly-11 on the dimer interface results in the complete crystallographic dimer dissociation of severe acute respiratory syndrome coronavirus 3C-like protease: Crystal structure with molecular dynamics simulations. J. Biol. Chem. 2008, 283, 554–564. [Google Scholar] [CrossRef] [Green Version]
- Zhang, S.; Zhong, N.; Ren, X.; Jin, C.; Xia, B. 1H, 13C and 15N resonance assignments of SARS-CoV main protease N-terminal domain. Biomol. NMR Assign. 2011, 5, 143–145. [Google Scholar] [CrossRef] [Green Version]
- Lim, L.; Shi, J.; Mu, Y.; Song, J. Dynamically-driven enhancement of the catalytic machinery of the SARS 3C-like protease by the S284-T285-I286/A mutations on the extra domain. PLoS ONE 2014, 9, e101941. [Google Scholar] [CrossRef]
- Shi, J.; Song, J. The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain. FEBS J. 2006, 273, 1035–1045. [Google Scholar] [CrossRef]
- Zhong, N.; Zhang, S.; Zou, P.; Chen, J.; Kang, X.; Li, Z.; Liang, C.; Jin, C.; Xia, B. Without its N-finger, the main protease of severe acute respiratory syndrome coronavirus can form a novel dimer through its C-terminal domain. J. Virol. 2008, 82, 4227–4234. [Google Scholar] [CrossRef] [Green Version]
- Xia, B.; Kang, X. Activation and maturation of SARS-CoV main protease. Protein Cell 2011, 2, 282–290. [Google Scholar] [CrossRef] [Green Version]
- Vuong, W.; Khan, M.B.; Fischer, C.; Arutyunova, E.; Lamer, T.; Shields, J.; Saffran, H.A.; McKay, R.T.; van Belkum, M.J.; Joyce, M.; et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. BioRxiv 2020. [Google Scholar] [CrossRef]
- Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 2020, 582, 289–293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jin, Z.; Zhao, Y.; Sun, Y.; Zhang, B.; Wang, H.; Wu, Y.; Zhu, Y.; Zhu, C.; Hu, T.; Du, X.; et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat. Struct. Mol. Biol. 2020, 27, 529–532. [Google Scholar] [CrossRef] [PubMed]
- Serafin, M.B.; Bottega, A.; Foletto, V.S.; da Rosa, T.F.; Horner, A.; Horner, R. Drug repositioning is an alternative for the treatment of coronavirus COVID-19. Int. J. Antimicrob. Agents 2020, 55, 105969. [Google Scholar] [CrossRef] [PubMed]
- Leif, P. In Silico Molecular Dynamics Docking of Drugs to the Inhibitory Active Site of SARS-CoV-2 Protease and Their Predicted Toxicology and ADME. ChemRxiv 2020. [Google Scholar] [CrossRef]
- Serafin, M.B.; Horner, R. Drug repositioning, a new alternative in infectious diseases. Braz. J. Infect. Dis. 2018, 22, 252–256. [Google Scholar] [CrossRef] [PubMed]
- Ashburn, T.T.; Thor, K.B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 2004, 3, 673–683. [Google Scholar] [CrossRef]
- Arun, K.G.; Sharanya, C.S.; Abhithaj, J.; Francis, D.; Sadasivan, C. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target. J. Biomol. Struct. Dyn. 2020, 1–12. [Google Scholar] [CrossRef]
- Khan, A.; Ali, S.S.; Khan, M.T.; Saleem, S.; Ali, A.; Suleman, M.; Babar, Z.; Shafiq, A.; Khan, M.; Wei, D.Q. Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro). J. Biomol. Struct. Dyn. 2020, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Gao, K.; Nguyen, D.D.; Chen, J.; Wang, R.; Wei, G.W. Repositioning of 8565 Existing Drugs for COVID-19. J. Phys. Chem. Lett. 2020, 11, 5373–5382. [Google Scholar] [CrossRef] [PubMed]
- Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020, 30, 269–271. [Google Scholar] [CrossRef] [PubMed]
- Gao, J.; Tian, Z.; Yang, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends 2020, 14, 72–73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, J.; Cao, R.; Xu, M.; Wang, X.; Zhang, H.; Hu, H.; Li, Y.; Hu, Z.; Zhong, W.; Wang, M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020, 6, 1–4. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.; Ma, X.; Yu, F.; Liu, J.; Zou, F.; Pan, T.; Zhang, H. Teicoplanin potently blocks the cell entry of 2019-nCoV. BioRxiv 2020. [Google Scholar] [CrossRef] [Green Version]
- Mahapatra, S.; Nath, P.; Chatterjee, M.; Das, N.; Kalita, D.; Roy, P.; Satapathi, S. Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking. MedRxiv 2020. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Zhang, J.; Wang, N.; Li, H.; Shi, Y.; Guo, G.; Liu, K.; Zeng, H.; Zou, Q. Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening. BioRxiv 2020. [Google Scholar] [CrossRef] [Green Version]
- Kumar, Y.; Singh, H.; Patel, C.N. In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J. Infect. Public Health 2020. [Google Scholar] [CrossRef]
- Alméciga-Díaz, C.J.; Pimentel-Vera, L.; Caro, A.; Mosquera, A.; Castellanos Moreno, C.A.; Manosalva Rojas, J.P.; Díaz-Tribaldos, D.C. Virtual Screening of Potential Inhibitors for SARS-CoV-2 Main Protease. Prepr. Org. 2020. [Google Scholar] [CrossRef] [Green Version]
- Cesar, M.-M.; Alejandro, R.-L. Identification of Potential Inhibitors of SARS-CoV-2 Main Protease via a Rapid In-Silico Drug Repurposing Approach. ChemRxiv 2020. [Google Scholar] [CrossRef]
- Yogesh, K.; Harvijay, S. In Silico Identification and Docking-Based Drug Repurposing Against the Main Protease of SARS-CoV-2, Causative Agent of COVID-19. ChemRxiv 2020. [Google Scholar] [CrossRef]
- Wu, C.; Liu, Y.; Yang, Y.; Zhang, P.; Zhong, W.; Wang, Y.; Wang, Q.; Xu, Y.; Li, M.; Li, X.; et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B 2020, 10, 766–788. [Google Scholar] [CrossRef] [PubMed]
- Vatansever, E.C.; Yang, K.; Kratch, K.C.; Drelich, A.; Cho, C.C.; Mellot, D.M.; Xu, S.; Tseng, C.K.; Liu, W.R. Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19. BioRxiv 2020. [Google Scholar] [CrossRef]
- Liu, S.; Zheng, Q.; Wang, Z. Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus. Bioinformatics 2020, 36, 3295–3298. [Google Scholar] [CrossRef] [PubMed]
- Cheng, B.; Li, T. Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking. Biotechniques 2020. [Google Scholar] [CrossRef]
- De Meyer, S.; Bojkova, D.; Cinatl, J.; Van Damme, E.; Buyck, C.; Van Loock, M.; Woodfall, B.; Ciesek, S. Lack of antiviral activity of darunavir against SARS-CoV-2. Int. J. Infect. Dis. 2020, 97, 7–10. [Google Scholar] [CrossRef]
- Mak, K.-K.; Pichika, M.R. Artificial intelligence in drug development: Present status and future prospects. Drug Discov. Today 2019, 24, 773–780. [Google Scholar] [CrossRef]
- Ke, Y.Y.; Peng, T.T.; Yeh, T.K.; Huang, W.Z.; Chang, S.E.; Wu, S.H.; Hung, H.C.; Hsu, T.A.; Lee, S.J.; Song, J.S.; et al. Artificial intelligence approach fighting COVID-19 with repurposing drugs. Biomed. J. 2020. [Google Scholar] [CrossRef]
- Richardson, P.; Griffin, I.; Tucker, C.; Smith, D.; Oechsle, O.; Phelan, A.; Rawling, M.; Savory, E.; Stebbing, J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020, 395, e30–e31. [Google Scholar] [CrossRef] [Green Version]
- Yassine, H.M.; Shah, Z. How could artificial intelligence aid in the fight against coronavirus? Expert Rev. Anti-Infect. Ther. 2020, 18, 493–497. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gimeno, A.; Mestres-Truyol, J.; Ojeda-Montes, M.J.; Macip, G.; Saldivar-Espinoza, B.; Cereto-Massagué, A.; Pujadas, G.; Garcia-Vallvé, S. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. Int. J. Mol. Sci. 2020, 21, 3793. [Google Scholar] [CrossRef] [PubMed]
- Tang, B.; He, F.; Liu, D.; Fang, M.; Wu, Z.; Xu, D. AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2. BioRxiv 2020. [Google Scholar] [CrossRef] [Green Version]
- Park, S.J.; Yu, K.M.; Kim, Y.I.; Kim, S.M.; Kim, E.H.; Kim, S.G.; Kim, E.J.; Casel, M.A.B.; Rollon, R.; Jang, S.G.; et al. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. Mbio 2020, 11, e01114–e01120. [Google Scholar] [CrossRef]
- Walmsley, S.; Bernstein, B.; King, M.; Arribas, J.; Beall, G.; Ruane, P.; Johnson, M.; Johnson, D.; Lalonde, R.; Japour, A.; et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 2002, 346, 2039–2046. [Google Scholar] [CrossRef]
- Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 2020, 382, 1787–1799. [Google Scholar] [CrossRef]
- Cheng, C.Y.; Lee, Y.L.; Chen, C.P.; Lin, Y.C.; Liu, C.E.; Liao, C.H.; Cheng, S.H. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J. Microbiol. Immunol. Infect. 2020, 53, 488–492. [Google Scholar] [CrossRef]
- Gautret, P.; Lagier, J.C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 2020, 56, 105949. [Google Scholar] [CrossRef]
- Andreani, J.; Le Bideau, M.; Duflot, I.; Jardot, P.; Rolland, C.; Boxberger, M.; Wurtz, N.; Rolain, J.M.; Colson, P.; La Scola, B.; et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb. Pathog. 2020, 145, 104228. [Google Scholar] [CrossRef]
- Sohag, A.A.M.; Hannan, M.A.; Rahman, S.; Hossain, M.; Hasan, M.; Khan, M.K.; Khatun, A.; Dash, R.; Uddin, M.J. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. Drug Dev. Res. 2020. [Google Scholar] [CrossRef]
- Lovato, E.C.; Barboza, L.N.; Wietzikoski, S.; Vasques de Souza, A.N.; Auth, P.A.; Gasparotto Junior, A.; Lívero, F.A. Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Curr. Pharm. Des. 2020, 26, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Jeong, G.U.; Song, H.; Yoon, G.Y.; Kim, D.; Kwon, Y.-C. Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review. Front. Microbiol. 2020, 11, 1723. [Google Scholar] [CrossRef] [PubMed]
- Bayoumy, A.B.; de Boer, N.K.H.; Ansari, A.R.; Crouwel, F.; Mulder, C.J.J. Unrealized potential of drug repositioning in Europe during COVID-19 and beyond: A physician’s perspective. J. Pharm. Policy Pract. 2020, 13, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Chang, R.; Sun, W.-Z. Repositioning chloroquine as antiviral prophylaxis against COVID-19: Potential and challenges. Drug Discov. Today 2020. [Google Scholar] [CrossRef]
- Ulm, J.W.; Nelson, S.F. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates. Transbound. Emerg. Dis. 2020. [Google Scholar] [CrossRef]
- Plewczynski, D.; Hoffmann, M.; von Grotthuss, M.; Ginalski, K.; Rychewski, L. In silico prediction of SARS protease inhibitors by virtual high throughput screening. Chem. Biol. Drug Des. 2007, 69, 269–279. [Google Scholar] [CrossRef]
- Kumar, V.; Dhanjal, J.K.; Kaul, S.C.; Wadhwa, R.; Sundar, D. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity. J. Biomol. Struct. Dyn. 2020, 1–13. [Google Scholar] [CrossRef]
- Bhardwaj, V.K.; Singh, R.; Sharma, J.; Rajendran, V.; Purohit, R.; Kumar, S. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. J. Biomol. Struct. Dyn. 2020, 1–10. [Google Scholar] [CrossRef]
- Enmozhi, S.K.; Raja, K.; Sebastine, I.; Joseph, J. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: An in silico approach. J. Biomol. Struct. Dyn. 2020, 1–7. [Google Scholar] [CrossRef]
- Ul Qamar, M.T.; Alqahtani, S.M.; Alamri, M.A.; Chen, L.L. Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants. J. Pharm. Anal. 2020. [Google Scholar] [CrossRef]
- Ton, A.T.; Gentile, F.; Hsing, M.; Ban, F.; Cherkasov, A. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds. Mol. Inform. 2020, 39, e2000028. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mishra, A.; Pathak, Y.; Tripathi, V. Natural compounds as potential inhibitors of novel coronavirus (COVID-19) main protease: An in silico study. Res. Sq. 2020. [Google Scholar] [CrossRef] [Green Version]
- Macchiagodena, M.; Pagliai, M.; Procacci, P. Identification of Potential Binders of the Main Protease 3CL(pro) of the COVID-19 via Structure-Based Ligand Design and Molecular Modeling. Chem. Phys. Lett. 2020, 750, 137489. [Google Scholar] [CrossRef] [PubMed]
- Mothay, D.; Ramesh, K.V. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock. Virusdisease 2020, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Kuo, C.J.; Liu, H.G.; Lo, Y.K.; Seong, C.M.; Lee, K.I.; Jung, Y.S.; Liang, P.H. Individual and common inhibitors of coronavirus and picornavirus main proteases. FEBS Lett. 2009, 583, 549–555. [Google Scholar] [CrossRef] [Green Version]
- Pillaiyar, T.; Manickam, M.; Namasivayam, V.; Hayashi, Y.; Jung, S.H. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. J. Med. Chem. 2016, 59, 6595–6628. [Google Scholar]
- Drag, M.; Salvesen, G.S. Emerging principles in protease-based drug discovery. Nat. Rev. Drug Discov. 2010, 9, 690–701. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Zhang, Z.; Phoo, W.W.; Loh, Y.R.; Wang, W.; Liu, S.; Chen, M.W.; Hung, A.W.; Keller, T.H.; Luo, D.; et al. Structural Dynamics of Zika Virus NS2B-NS3 Protease Binding to Dipeptide Inhibitors. Structure 2017, 25, 1242–1250.e1243. [Google Scholar] [CrossRef] [Green Version]
- Verschueren, K.H.; Pumpor, K.; Anemuller, S.; Chen, S.; Mesters, J.R.; Hilgenfeld, R. A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters. Chem. Biol. 2008, 15, 597–606. [Google Scholar] [CrossRef] [Green Version]
- Lenci, E.; Trabocchi, A. Peptidomimetic toolbox for drug discovery. Chem Soc. Rev. 2020, 49, 3262–3277. [Google Scholar] [CrossRef]
- Bacha, U.; Barrila, J.; Gabelli, S.B.; Kiso, Y.; Mario Amzel, L.; Freire, E. Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro). Chem. Biol. Drug Des. 2008, 72, 34–49. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, Y.; Lovell, S.; Tiew, K.C.; Mandadapu, S.R.; Alliston, K.R.; Battaile, K.P.; Groutas, W.C.; Chang, K.O. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. 2012, 86, 11754–11762. [Google Scholar] [CrossRef] [Green Version]
- Poulsen, A.; Kang, C.; Keller, T.H. Drug design for flavivirus proteases: What are we missing? Curr. Pharm. Des. 2014, 20, 3422–3427. [Google Scholar] [CrossRef] [PubMed]
- Kang, C.; Gayen, S.; Wang, W.; Severin, R.; Chen, A.S.; Lim, H.A.; Chia, C.S.; Schuller, A.; Doan, D.N.; Poulsen, A.; et al. Exploring the binding of peptidic West Nile virus NS2B-NS3 protease inhibitors by NMR. Antivir. Res. 2013, 97, 137–144. [Google Scholar] [CrossRef] [PubMed]
- Yang, H.; Xie, W.; Xue, X.; Yang, K.; Ma, J.; Liang, W.; Zhao, Q.; Zhou, Z.; Pei, D.; Ziebuhr, J.; et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005, 3, e324. [Google Scholar] [CrossRef]
- Xue, X.; Yu, H.; Yang, H.; Xue, F.; Wu, Z.; Shen, W.; Li, J.; Zhou, Z.; Ding, Y.; Zhao, Q.; et al. Structures of two coronavirus main proteases: Implications for substrate binding and antiviral drug design. J. Virol. 2008, 82, 2515–2527. [Google Scholar] [CrossRef] [Green Version]
- Ren, Z.; Yan, L.; Zhang, N.; Guo, Y.; Yang, C.; Lou, Z.; Rao, Z. The newly emerged SARS-like coronavirus HCoV-EMC also has an “Achilles’ heel”: Current effective inhibitor targeting a 3C-like protease. Protein Cell 2013, 4, 248–250. [Google Scholar] [CrossRef]
- Kim, Y.; Liu, H.; Galasiti Kankanamalage, A.C.; Weerasekara, S.; Hua, D.H.; Groutas, W.C.; Chang, K.O.; Pedersen, N.C. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016, 12, e1005531. [Google Scholar] [CrossRef]
- Ma, C.; Sacco, M.D.; Hurst, B.; Townsend, J.A.; Hu, Y.; Szeto, T.; Zhang, X.; Tarbet, B.; Marty, M.T.; Chen, Y.; et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020, 30, 678–692. [Google Scholar] [CrossRef]
- Blanchard, J.E.; Elowe, N.H.; Huitema, C.; Fortin, P.D.; Cechetto, J.D.; Eltis, L.D.; Brown, E.D. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem. Biol. 2004, 11, 1445–1453. [Google Scholar] [CrossRef] [Green Version]
- Choudhury, C. Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease. J. Biomol. Struct. Dyn. 2020, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Hatada, R.; Okuwaki, K.; Mochizuki, Y.; Handa, Y.; Fukuzawa, K.; Komeiji, Y.; Okiyama, Y.; Tanaka, S. Fragment Molecular Orbital Based Interaction Analyses on COVID-19 Main Protease—Inhibitor N3 Complex (PDB ID: 6LU7). J. Chem. Inf. Model. 2020. [Google Scholar] [CrossRef] [PubMed]
- Bzówka, M.; Mitusińska, K.; Raczyńska, A.; Samol, A.; Tuszyński, J.A.; Góra, A. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design. Int. J. Mol. Sci. 2020, 21, 3099. [Google Scholar] [CrossRef] [PubMed]
- Milan, S.; Vladimir, P.; Snezana, P.; Miroslav, A.; Slobodan, P.; Sanja, G. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel in Silico Method. ChemRxiv 2020. [Google Scholar] [CrossRef]
- Wei, P.; Fan, K.; Chen, H.; Ma, L.; Huang, C.; Tan, L.; Xi, D.; Li, C.; Liu, Y.; Cao, A.; et al. The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase. Biochem. Biophys. Res. Commun. 2006, 339, 865–872. [Google Scholar] [CrossRef]
- Chen, F.M.; Feng, M.C.; Chen, T.C.; Hsieh, M.H.; Kuo, S.H.; Chang, H.L.; Yang, C.J.; Chen, Y.H. Big data integration and analytics to prevent a potential hospital outbreak of COVID-19 in Taiwan. J. Microbiol. Immunol. Infect. 2020. [Google Scholar] [CrossRef]
PDB ID | Remarks | Reference |
---|---|---|
6Y2G | Complex structure | [36] |
6Y2F | Complex structure | [36] |
6Y2E | Free protease | [36] |
6LZE | In complex with 11a | [31] |
6M0K | In complex with 11b | [31] |
6WTJ | In complex with GC376 | [53] |
6WTK | In complex GC373 | [53] |
7BQY | In complex with N3 | [54] |
6LU7 | In complex with N3 | [54] |
7BUY | In complex with carmofur | [55] |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Li, Q.; Kang, C. Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. Microorganisms 2020, 8, 1250. https://doi.org/10.3390/microorganisms8081250
Li Q, Kang C. Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. Microorganisms. 2020; 8(8):1250. https://doi.org/10.3390/microorganisms8081250
Chicago/Turabian StyleLi, Qingxin, and CongBao Kang. 2020. "Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease" Microorganisms 8, no. 8: 1250. https://doi.org/10.3390/microorganisms8081250